PROM1 and neoplasm: Third, TMZ reduced the tumor‐initiating capacity of shRNACD133‐1/CD133+ cell expressing shRNA‐resistant CD133(1–862) mutant, but not shRNA‐resistant wild‐type CD133 (Figure 7F).